Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)

NCT ID: NCT01863407

Last Updated: 2013-05-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 480 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2014-11-30

Brief Summary

This study is being conducted to determine whether Dexamethasone-Allantoin-Metronidazole (DAM) Solution can accelerate recovery of gastrointestinal function following abdominal operation when compared with a placebo.

Detailed Description

Postoperative ileus (POI) is temporary slowing down or stopping of bowel function and a slowing down of movement of contents of the intestines. This functional impairment persists for a variable duration following surgery, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. When POI persists for more than 5 days, it is generally considered severe, sometimes referred to as complicated or prolonged POI, and increases the risk for related morbidity. This is a randomized, controlled, double-blind study designed to evaluate the tolerability and efficacy of DAM solution for the treatment of POI in patients following abdominal operation. It will be conducted at multiple centers in China. A total of 480 patients will be enrolled in the study. Patient participation in the study will last for up to postoperative day 7 [POD 7] , with follow-up safety assessments to occur 7 days after the operation.The treatment outcome measures include: 1) GI2(Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food). 2) Time to ready for discharge. 3) Time to the first flatus.

Conditions

Postoperative Ileus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

DAM Solution

Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure

Group Type: EXPERIMENTAL

DAM

Intervention Type: DRUG

composed of dexamethasone, allantoin and metronidazole

Normal Saline

Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure

Group Type: PLACEBO_COMPARATOR

Normal Saline

Intervention Type: DRUG

Normal Saline 250ml

Interventions

DAM

composed of dexamethasone, allantoin and metronidazole

Intervention Type: DRUG

Normal Saline

Normal Saline 250ml

Intervention Type: DRUG

Other Intervention Names

Dexamethasone-Allantoin-Metronidazole (DAM) Solution; NS

Eligibility Criteria

Inclusion Criteria

• are either Male or Female at least 18 years of age;
• Had an American Society of Anesthesiologists (ASA) Physical Status Score of I-III;
• Were scheduled to undergo partial small or large BR with primary anastomosis (performed completely by laparotomy); biliary-enteric Roux-en-Y anastomosis surgery;
• BMI (kg/m^2) index≥15 and ≤30;
• Understood the procedures, agreed to participate in the study program, and voluntarily signed the informed consent form.

Exclusion Criteria

• Had complete bowel obstruction;
• Were scheduled for a total colectomy;
• Were scheduled for a ileal pouch-anal anastomosis;
• Were scheduled for a colostomy, ileostomy;
• Had a history of gastrectomy, total colectomy, gastric bypass, short bowel syndrome, or multiple previous abdominal surgeries;
• Had clinically significant laboratory abnormalities on screening(such as: ALT, AST were more than 2 times the upper limit of normal value; Cr is greater than 1.2 times the upper normal limit, according to the center for the study of the normal value range);
• Applied the intravenous or epidural postoperative analgesia pump;
• Bowel preparation does not meet the requirements;
• Were allergy to components of the investigational drug (allantoin, metronidazole, dexamethasone);
• Had used illicit drugs or had abused alcohol;
• Had a history of illness, or behavior (e.g., depression, psychosis) that in the opinion of the investigator might confound the results of the study or pose an additional risk in participating in the study;
• Women who were pregnant, and women who were of childbearing potential and not using method of birth control;
• Had participated in another clinical drug trial within the last 3 months;
• Were not agreed to participate the clinical trial by investigators.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Bozhiyin T&S Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ying-jiang Ye, professor

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Center for Drug Clinical Research, Shanghai University of Chinese Medicine

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Qing-shan Zheng, professor

Role: CONTACT

qingshan.zheng@drugchina.net

13817078595

Other Identifiers

BZY 001

Identifier Type: -

Identifier Source: org_study_id